Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.
Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.